STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs.

Background Healthcare professionals are often reluctant to deprescribe fall-risk-increasing drugs (FRIDs). Lack of knowledge and skills form a significant barrier and furthermore, there is no consensus on which medications are considered as FRIDs despite several systematic reviews. To support clinic...

Descripción completa

Detalles Bibliográficos
Publicado en:Age & Ageing Vol. 50; no. 4; pp. 1189 - 1200
Autores principales: Seppala, Lotta J, Petrovic, Mirko, Ryg, Jesper, Bahat, Gulistan, Topinkova, Eva, Szczerbińska, Katarzyna, Cammen, Tischa J M van der, Hartikainen, Sirpa, Ilhan, Birkan, Landi, Francesco, Morrissey, Yvonne, Mair, Alpana, Gutiérrez-Valencia, Marta, Emmelot-Vonk, Marielle H, Mora, María Ángeles Caballero, Denkinger, Michael, Crome, Peter, Jackson, Stephen H D, Correa-Pérez, Andrea, Knol, Wilma
Formato: Artículo
Publicado: Oxford University Press / USA Jul2021
Materias:
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:Background Healthcare professionals are often reluctant to deprescribe fall-risk-increasing drugs (FRIDs). Lack of knowledge and skills form a significant barrier and furthermore, there is no consensus on which medications are considered as FRIDs despite several systematic reviews. To support clinicians in the management of FRIDs and to facilitate the deprescribing process, STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk) and a deprescribing tool were developed by a European expert group. Methods STOPPFall was created by two facilitators based on evidence from recent meta-analyses and national fall prevention guidelines in Europe. Twenty-four panellists chose their level of agreement on a Likert scale with the items in the STOPPFall in three Delphi panel rounds. A threshold of 70% was selected for consensus a priori. The panellists were asked whether some agents are more fall-risk-increasing than others within the same pharmacological class. In an additional questionnaire, panellists were asked in which cases deprescribing of FRIDs should be considered and how it should be performed. Results The panellists agreed on 14 medication classes to be included in the STOPPFall. They were mostly psychotropic medications. The panellists indicated 18 differences between pharmacological subclasses with regard to fall-risk-increasing properties. Practical deprescribing guidance was developed for STOPPFall medication classes. Conclusion STOPPFall was created using an expert Delphi consensus process and combined with a practical deprescribing tool designed to optimise medication review. The effectiveness of these tools in falls prevention should be further evaluated in intervention studies.